Press Releases

06/16/2016

SeraCare and NIST Partner on Development of Circulating Tumor DNA Reference Standards for Diagnostics

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed of a three-year Cooperative Research And Development Agreement (CRADA) to advance development of circulating tumor DNA (ctDNA) diagnostic assay reference standard materials.

07/28/2015

SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today at the American Association of Clinical Chemistry (AACC) meeting that it has signed a licensing agreement with the University of California, San Francisco (UCSF) for the use of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast cell line material as a component for creating “patient-like” reference materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal abnormalities.

07/08/2015

SeraCare Life Sciences’ Precision Medicine Unit Launches New Product to Ensure Accuracy of NGS Assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.

06/26/2015

SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.